Patented Platform Technology
Bacillus subtilis MM40® (DSM 21097) is a patented, DSMZ-deposited spore-former. We develop applications for health, skincare and biotechnology.
Classical probiotics such as Lactobacillus and Bifidobacterium lose up to 99% of their viability on the way through the stomach. Bacillus subtilis MM40®, as a natural spore-former, withstands gastric acid, heat and storage without refrigeration.
As a gram-positive spore-former, B. subtilis MM40® forms resistant endospores that withstand gastric acid, heat and storage without refrigeration for up to 2 years.
The strain is capable of producing surfactin - a cyclic lipopeptide with surface-active properties that is described in research as a subject of intensive investigation.
Fully sequenced and deposited at the DSMZ as MM40® (DSM 33619). Identity confirmed by CeGaT laboratory analysis, EU patent granted.
All three designations refer to the same bacterial strain. Genetic identity was confirmed by Whole-Genome Sequencing (CeGaT GmbH, 27.01.2022): DSM 21097 and DSM 33619 are genetically identical.
Individual deposit number at the German Collection of Microorganisms and Cell Cultures (DSMZ) in Braunschweig. The original scientific reference number of the strain.
International patent deposit under the Budapest Treaty (20.08.2020). This number secures the patent protection of the strain and is the basis for the granted EU patent EP 3 964 195.
Registered EU word mark No. 018279328 (registered 27.02.2021). Nice classes 1, 5, 32 - the commercial brand name for scientific publications and the B2B market.
Research and application fields in which the strain has been investigated so far.
In a placebo-controlled, randomised study with 70 participants, changes in metabolic parameters were investigated and documented over 12 weeks.
The study showed shifts in the composition of participants’ gut flora, particularly in Firmicutes/Bacteroidetes ratios and specific gut barrier markers.
In vitro investigations at UKSH Lübeck showed inhibition zones against selected reference strains. These results serve as a basis for further research.
Spore-formers of the species B. subtilis are the subject of extensive immunological research. The interaction with GALT (Gut-Associated Lymphoid Tissue) is described in the scientific literature.
The antimicrobial and surface-active properties of surfactin are discussed in scientific publications as relevant for dermatological and cosmetic applications.
The changes in specific biomarkers observed in the clinical study are associated in the scientific literature with aspects of biological aging.
In a placebo-controlled, randomised study with 70 participants over 12 weeks, the following changes were observed in the verum group compared to the placebo group:
Note: the data come from a single-centre study (n = 70; microbiome sub-analysis n = 38). Further research is required. These are not authorised health claims under EU Regulation 1924/2006. Source: Vogel W, Minch S, Prydyus I, Kryzhanovska N, 2026.
Explore the Science →One of the few B. subtilis strains worldwide with a completed, placebo-controlled, randomised study in humans.
In vitro inhibition zones against selected reference strains including multi-resistant pathogens - documented at UKSH Lübeck.
EU Patent EP3964195 granted. Strain deposited at the German Collection of Microorganisms and Cell Cultures (DSMZ).
Capability to produce surfactin - a biosurfactant intensively investigated in research with diverse application fields.
Magnat Vital has been researching Bacillus subtilis MM40® since 2011. The strain is patented, deposited with the DSMZ and investigated in a clinical study. More than 100,000 users apply it today.
Genome analysis, strain deposition and clinical investigation come before application.
Strain characterisation, production and final testing take place in Germany.
We work with research institutions, health professionals and distribution partners.
Whether as a raw material supplier, research partner or within a joint venture - we are open to diverse cooperation models.